All In Biotech

Drug Trial Radar · NCT07024784

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 377 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

377

Planned (sponsor's estimate)

Start

Jul 30, 2025

Primary completion

Jan 2028

Study completion Feb 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
GOG Foundation
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Conditions

  • Gynecologic Cancers
  • Platinum-Sensitive Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer (PSOC)

Interventions

  • IMGN151Drug

    Intravenous (IV) infusion

  • CarboplatinDrug

    Intravenous (IV) infusion

  • BevacizumabDrug

    Intravenous (IV) infusion

  • OlaparibDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Up to approximately 3 years
  2. Percentage of Participants with Adverse Events (AE)Time frame: Up to approximately 3 years

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Start Los Angeles /ID# 281533

    Los Angeles, California · Recruiting

  • University of Colorado Hospital- Aurora /ID# 278232

    Aurora, Colorado · Recruiting

  • University Of Minnesota /ID# 277850

    Minneapolis, Minnesota · Recruiting

  • Holy Name Medical Center /ID# 279017

    Teaneck, New Jersey · Recruiting

  • SUNY Upstate Medical University - Syracuse /ID# 277305

    Syracuse, New York · Recruiting

  • University of Cincinnati Medical Center. /ID# 278925

    Cincinnati, Ohio · Recruiting

  • University Hospitals Cleveland Medical Center /ID# 279601

    Cleveland, Ohio · Recruiting

  • OU Health - Stephenson Cancer Center /ID# 277656

    Oklahoma City, Oklahoma · Recruiting

  • Providence Portland Medical Center /ID# 277727

    Portland, Oregon · Recruiting

  • Women & Infants Hospital /ID# 277930

    Providence, Rhode Island · Recruiting

  • SCRI Oncology Partners /ID# 279733

    Nashville, Tennessee · Recruiting

  • Texas Oncology-Austin North /ID# 279958

    Austin, Texas · Recruiting

  • Next Virginia /ID# 279684

    Fairfax, Virginia · Recruiting

  • Rambam Health Care Campus- Haifa /ID# 276004

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center /ID# 275854

    Jerusalem, Israel · Recruiting

  • Rabin Medical Center /ID# 279142

    Petah Tikva, Central District, Israel · Recruiting

  • The Chaim Sheba Medical Center /ID# 275997

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center /ID# 275852

    Tel Aviv, Tel Aviv, Israel · Recruiting

  • Hyogo Cancer Center /ID# 276940

    Akashi-shi, Hyōgo, Japan · Recruiting

  • National Cancer Center Hospital /ID# 276715

    Chuo-Ku, Tokyo, Japan · Recruiting

  • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 276711

    Koto-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.